Klemp Walter V's Form 4 filing
Moleculin Biotech, Inc. (MBRX) · filed Jun 23, 2025
- Accession no.
- 0001437749-25-021050
- Filed
- Jun 23, 2025, 4:35 PM ET
- Trade date
- Jun 20-23, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market purchases total $250.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Klemp Walter VCIK 0000938419 | Director, Officer (CEO and President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | Common Stock | MOption exerciseAcquired | +3,750 | –F1 | – | 62,046 | Direct | |
| Jun 20, 2025 | Common Stock | FTax withholdingDisposed | −914 | $0.267 | −$244.04 | 61,132 | Direct | |
| Jun 22, 2025 | Common Stock | MOption exerciseAcquired | +8,990 | –F1 | – | 70,122 | Direct | |
| Jun 22, 2025 | Common Stock | FTax withholdingDisposed | −2,190 | $0.267 | −$584.73 | 67,932 | Direct | |
| Jun 23, 2025 | Common Stock | PPurchaseAcquired | +675,675 | $0.37F5 | +$249,999.75 | 743,607 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | Common Stock | MOption exerciseDisposed | −3,750 | $0.00 | $0 | 391,446 | Direct | |
| Jun 22, 2025 | Common Stock | MOption exerciseDisposed | −8,990 | $0.00 | $0 | 382,456 | Direct | |
| Jun 23, 2025 | Common Stock | PPurchaseDisposed | −2,027,025 | –F5 | – | 2,409,481 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Restricted stock units convert into common stock on a one-for-one basis.
Referenced by the price of 2 transactions in Table I.
- F5
On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.